Technology | January 19, 2015

FDA Grants HDE For Pacemaker That Regulates Hypertension

Device used to control drug-resistant hypertension via implantable pulse generator

CVRx, Barostim neo Legacy System, pacemaker, hypertension, FDA, HDE

January 19, 2015 — The U.S. Food and Drug Administration (FDA) has granted a humanitarian device exemption for the CVRx Inc. Barostim neo Legacy System.

The Barostim neo System is a programmable, minimally invasive device that consists of an implantable pulse generator (IPG), a 2-mm electrode and an external programmer. Barostim therapy is designed to trigger the natural blood pressure regulation system by electrically activating the carotid baroreceptors. The device is commercially available in Europe and the United States. The therapy is included in the joint European Society of Hypertension and European Society of Cardiology guidelines for the treatment of resistant hypertension published in June 2013.

The system is completed by connecting the IPG to electrical stimulation lead electrodes placed on the carotid sinus nerves on each side of the neck. The device provides controlled delivery of high-frequency, small electrical stimulation pulses to the carotid sinus. This has been shown to provide probable benefit to patients with resistant hypertension who have already been determined to respond to this treatment by lowering their systolic and diastolic blood pressure.

The Barostim neo Legacy System may be used in patients with resistant hypertension who were previously implanted in clinical trials with the Rheos Carotid Sinus Leads Models 1010R, 1010L, 1014L, and 1014R which have now been discontinued and are no longer available. Specifically, the approved IPG will replace an existing IPG in a patient whose battery is depleted and needs to be replaced and/or electrode lead repair procedures are necessary.

Use of the Barostim neo Legacy System may help patients who achieved a significant lowering of their blood pressure during their participation in the clinical trial to maintain those results. Clinical trial results showed that in these patients the systolic and diastolic blood pressure was lowered by an average of 33.6 mmHg and 17.5 mmHg, respectively.

For more information: www.fda.gov

Related Content

A conformal array of flexible electrodes affixed to an inflated balloon catheter. The sensors have the ability to make measurements of temperature, force of contact and electrophysiological parameters, ability to customize diagnostic and therapeutic functions and offer real-time feedback. Photo by John Rogers, Northwestern University.

A conformal array of flexible electrodes affixed to an inflated balloon catheter. The sensors have the ability to make measurements of temperature, force of contact and electrophysiological parameters, ability to customize diagnostic and therapeutic functions and offer real-time feedback. Photo by John Rogers, Northwestern University.

News | EP Lab | September 08, 2020
September 8, 2020 — Researchers developed a new class of medical instruments equipped with an advanced soft electroni
Biosense Webster's Carto Prime Mapping Module offers new tools to help shorten ablation time. Left is an example of Coherent imaging showing conduction identification, conduction velocity vectors and conduction barrier zones. Top right, Carto Finder Module automatic visualization of region of interest. Below right, LAT Hybrid imaging, showing correct identification of PVC location based on catheter location in sinus rhythm, and automated visualization of PVC points.

Biosense Webster's Carto Prime Mapping Module offers new tools to help shorten ablation time. Left is an example of Coherent imaging showing conduction identification, conduction velocity vectors and conduction barrier zones. Top right, Carto Finder Module automatic visualization of region of interest. Below right, LAT Hybrid imaging, showing correct identification of PVC location based on catheter location in sinus rhythm, and automated visualization of PVC points.

News | EP Lab | September 03, 2020
September 3, 2020 – Biosense Webster launched its Carto 3 System Version 7 and the Carto Prime Mapping Module to enha
HRS study finds Frequent Coffee Consumption Lowers Chance of Arrhythmias. #HRS #HRS20 Heartrhythm20
News | EP Lab | May 28, 2020
May 28, 2020 – A recent study revealed that drinking a couple of cups of coffee per day does not lead to a greater ri
he Actus AcQMap EP 3-D mapping catheter used  to speed  electromapping and procedure times.

he Actus AcQMap EP 3-D mapping catheter used  to speed  electromapping and procedure times.

News | EP Lab | May 20, 2020
May 20, 2020 — Acutus Medical and Biotronik announced a new alliance to provide a comprehensive portfolio of...
Thermedical, a developer of thermal-ablation medical systems to treat ventricular tachycardia (VT), announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its Saline Enhanced Radiofrequency (SERF) Ablation system and Durablate catheter.
News | EP Lab | May 19, 2020
May 19, 2020 – Thermedical, a developer of thermal-ablation medical systems to treat ventricular tachycardia (VT), an
HRS presentations included BlueSync Evaluation study for Medtronic MyCareLink Heart mobile app and Micra TPS CED Study
News | EP Lab | May 14, 2020
May 14, 2020 – Medtronic announced results from late-breaking clinical trials evaluating the MyCareLink Heart mobile
Etripamil Nasal Spray Does Not Meet Primary Endpoint in Treating Supraventricular Tachycardia in the NODE-301 trial presented at Heart Rhythm 2020. #heartrhythm2020 #HRS2020
News | EP Lab | May 13, 2020
May 13, 2020 — The patient-administered nasal spray drug etripamil did not meet its primary endpoint in treating pati